28 March 2022 ORYZON announces appointment of Douglas V. Faller, MD, PhD as Global Chief Medical Officer and continues its expansion of US corporate activities
21 March 2022 ORYZON announces FDA approval of IND for FRIDA, a Phase Ib trial with iadademstat in R/R AML FLT3mut+ patients
2 March 2022 Epigenetics Symposium – From Genes to Chromatin to Therapeutics Philadelphia PA United States